32,967 Shares in Illumina, Inc. $ILMN Bought by Insight Wealth Strategies LLC

Key Points

• Insight Wealth Strategies LLC acquired 32,967 Illumina shares worth approximately $6.06 million during the second quarter. Institutional investors collectively own 89.42% of the company.
• Illumina reported quarterly EPS of $1.31, beating estimates of $1.23, while revenue rose 9.4% year over year to $1.16 billion. The company guided to fiscal 2026 EPS of $5.30–$5.40.
• Analyst sentiment remains mixed, with an average rating of Hold and a consensus price target of $188.40; meanwhile, insiders sold about $271.1 million of stock over the past 90 days.

Insight Wealth Strategies LLC acquired a new stake in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 2nd quarter, according to its most recent disclosure with the SEC. The fund acquired 32,967 shares of the life sciences company's stock, valued at approximately $6,062,000.

A number of other institutional investors also recently modified their holdings of the company. Elyxium Wealth LLC bought a new position in shares of Illumina during the fourth quarter worth about $25,000. Creative Capital Management Investments LLC lifted its stake in Illumina by 160.0% in the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company's stock valued at $26,000 after acquiring an additional 120 shares in the last quarter. TD Waterhouse Canada Inc. bought a new stake in Illumina in the 4th quarter valued at approximately $26,000. Laurel Wealth Advisors LLC acquired a new position in Illumina during the 4th quarter worth approximately $26,000. Finally, Activest Wealth Management grew its stake in shares of Illumina by 671.9% during the 4th quarter. Activest Wealth Management now owns 247 shares of the life sciences company's stock worth $32,000 after acquiring an additional 215 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Stock Performance

Shares of ILMN stock opened at $192.84 on Wednesday. The company has a fifty day moving average price of $182.28 and a two-hundred day moving average price of $149.70. Illumina, Inc. has a one year low of $88.00 and a one year high of $207.00. The stock has a market cap of $29.12 billion, a P/E ratio of 35.98, a P/E/G ratio of 2.70 and a beta of 1.44. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.23 by $0.08. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The company had revenue of $1.16 billion for the quarter, compared to analysts' expectations of $1.13 billion. During the same period in the prior year, the firm earned $1.19 EPS. Illumina's quarterly revenue was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities analysts predict that Illumina, Inc. will post 5.36 EPS for the current year.

Analyst Ratings Changes

Several research analysts recently commented on ILMN shares. TD Cowen increased their target price on shares of Illumina from $192.00 to $210.00 and gave the stock a "hold" rating in a report on Friday, July 31st. Citigroup lifted their price target on shares of Illumina from $95.00 to $113.00 and gave the company a "sell" rating in a research note on Monday, August 3rd. Canaccord Genuity Group increased their price objective on shares of Illumina from $190.00 to $205.00 and gave the stock a "hold" rating in a research note on Monday, August 3rd. Wall Street Zen upgraded Illumina from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. Finally, Daiwa Securities Group raised Illumina from a "neutral" rating to an "outperform" rating and set a $155.00 target price on the stock in a research report on Thursday, May 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, Illumina has an average rating of "Hold" and a consensus price target of $188.40.

Insiders Place Their Bets

In other Illumina news, CAO Scott D. Ericksen sold 500 shares of the firm's stock in a transaction on Friday, May 29th. The stock was sold at an average price of $160.00, for a total transaction of $80,000.00. Following the completion of the sale, the chief accounting officer owned 14,446 shares of the company's stock, valued at $2,311,360. This trade represents a 3.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction on Friday, June 5th. The stock was sold at an average price of $162.59, for a total transaction of $127,307.97. Following the transaction, the senior vice president directly owned 21,259 shares of the company's stock, valued at approximately $3,456,500.81. This trade represents a 3.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 1,519,744 shares of company stock worth $271,138,789. Company insiders own 2.90% of the company's stock.

Illumina Company Profile

Illumina, Inc NASDAQ: ILMN is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source